TIDMAGL
RNS Number : 2918X
Angle PLC
23 November 2017
For immediate release 23 November 2017
ANGLE plc ("the Company")
COLLABORATION WITH PHILIPS IN BREAST AND RECTAL CANCER
ANGLE to receive European research grants of GBP0.4 million
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that it has established a
collaboration with Philips to develop liquid biopsy solutions.
Philips has successfully secured a European Union research grant
worth EUR6.3 million, of which GBP0.4 million will flow to
ANGLE.
Philips has selected ANGLE's Parsortix(TM) system as the sole
system to be used for harvesting circulating tumor cells (CTCs) for
analysis in the research collaboration, which is an important area
of development for Philips following its restructuring in 2016 to
focus on healthcare.
The collaboration with Philips comes shortly after ANGLE's
announcement of its co-marketing agreement with QIAGEN and is part
of ANGLE's strategy to establish partnerships with a wide range of
large companies for the commercialisation of Parsortix(TM) . In the
year to 31 December 2016, of Philips' total revenues of EUR24.5
billion, EUR17.5 billion came from healthcare, which is their focus
for future growth.
The collaboration is planned for a four year period. It is
estimated that grant funding of GBP0.1 million and GBP0.2 million
will be received by ANGLE in the financial years ending 30 April
2018 and 2019, respectively. The remaining GBP0.1 million will
spread over the following three financial years.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"We are delighted to be working with Philips and the other
commercial partners on the development of new liquid biopsy
solutions. We look forward to joint commercialisation of these
solutions and to working closely with Philips going forward. This
is a further demonstration of ANGLE's strategy to partner with
large corporates to deliver widespread adoption of ANGLE's
Parsortix(TM) CTC harvesting system."
The press release issued by Philips today is reproduced in full
below.
PHILIPS
Press Information
November 23, 2017
Philips-led research consortium awarded EUR 6.3 million EU grant
to develop integrated approaches for personalized cancer
treatment
-- Four-year research project aims to increase accuracy of both
genetic and functional characterization of primary breast and
rectal cancer
-- Clinical research studies to be carried out at University
Medical Center Utrecht (the Netherlands) and the Institut National
de la Sante et de la Recherche Medicale (France)
Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX:
PHIA), a global leader in health technology, together with its
consortium partners, today announced that it has been awarded a EUR
6.3 million Horizon 2020 EU research grant to develop an integrated
approach for personalized cancer treatment. The four-year research
project, 'Liquid biopsies and IMAging for improved cancer care'
(LIMA), aims to increase the accuracy of both genetic and
functional characterization of primary breast cancer and rectal
cancer by combining two diagnostic technologies: advanced blood
tests called liquid biopsy and Magnetic Resonance Imaging (MRI).
The clinical research studies will be carried out at the University
Medical Center Universitair Medisch Centrum Utrecht in the
Netherlands, and the Institut National de la Sante et de la
Recherche Medicale in France.
Integrating personalized treatment into the clinical
workflow
Each patient and tumor is unique, and often a treatment that's
effective for one patient will be ineffective for another. The LIMA
project aims to develop and validate tools and techniques that can
be applied during the early stages of cancer treatment. This may
enable clinicians to better understand the effectiveness of their
approach, and to potentially adapt further steps in the individual
treatment of the patient.
Liquid biopsies, advanced laboratory analysis based on routinely
drawn blood samples, support diagnosis by providing in-depth
genetic information about tumors and metastases in the body. The
analysis can be based on circulating tumor DNA (ct-DNA) or
Circulating Tumor Cells (CTC) contained in the blood samples. MRI
gives physicians information about the location of the cancer and
functional information about the tumor tissue composition. For
example, diffusion weighted MRI and perfusion MRI, well-known
imaging biomarkers in oncology, will be further developed for tumor
detection and characterization in order to provide comprehensive
and quantitative information for an integral diagnostic approach.
In addition, properties of MRI contrast at and around the tumor
will be analyzed to shed light on the tumor grade and biological
status, a field of imaging sciences called 'radiomics'.
"In collaboration with our partners we will combine a range of
liquid biopsy technologies, which give us more detailed molecular
information, with advanced MRI techniques, which could enable us to
better understand the impact of treatment at an early stage," said
Hans Hofstraat, innovation program manager, Philips. "This has the
potential to improve patient outcomes and potentially represents a
significant step forward in delivering personalized cancer
treatment."
"With liquid biopsies we can analyze circulating tumor DNA and
tumor cells in cancer that's advanced in a specific part of the
body," said Alain Thierry, Research Director, at the Institut
National de la Santé et de la Recherche Medicale (INSERM),
Montpellier, France. "This technique is an important emerging field
in diagnostics, particularly in oncology, and is starting to have a
positive impact on patient care."
"This project will allow us to build methods to look inside the
body in much more detail, which has the potential to improve the
treatment we provide and make a significant positive impact on the
lives of our patients," said Kenneth Gilhuijs, associate professor
and research coordinator at University Medical Center (UMC)
Utrecht, the Netherlands. "By understanding the impact of treatment
at an early stage, we will be able to deliver more targeted and
effective therapy."
Alongside Philips, INSERM and UMC Utrecht, the project involves
several SMEs that have developed innovative technologies for liquid
biopsies: Agena Bioscience GmbH (Germany), DiaDx (France) and
Stilla Technologies (France) provide technologies for analyzing
ct-DNA, ANGLE plc (UK) for CTC isolation and ALS Automation Lab
Solutions GmbH (Germany) for single CTC detection and
selection."
Horizon 2020 is the largest-ever EU Research and Innovation
program, with the goal of ensuring Europe produces world-class
science, removes barriers to innovation and makes it easier for the
public and private sectors to work together in delivering
innovation.
For further information, please contact:
Mark Groves
Philips Innovation & Strategy
Tel.: +31 631 639 916
E-mail: mark.grove@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips' health
technology portfolio generated 2016 sales of EUR 17.4 billion and
employs approximately 73,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix(TM) system has a CE Mark
for Europe and FDA authorisation is in process for the United
States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRPGGMPGUPMPGP
(END) Dow Jones Newswires
November 23, 2017 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024